Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis. Pro, B., Kim, Y. H., Ortiz-Romero, P. L., Sokol, L., Scarisbrick, J., Musiek, A., Vermeer, M., Dummer, R., Halwani, A., Fierro, M., Moriya, J., Leoni, M., Bagot, M. AMER SOC CLINICAL ONCOLOGY. 2019
View details for Web of Science ID 000487345806301